Method: The medical charts of patients treated with intravitreal anti-vascular endothelial growth factor anti-vascular endothelial growth factor (VEGF) (bevacizumab-ranibizumab) for retinal vascular disorders or age-related macular degeneration (AMD) from January 2011 to January 2015 were retrospectively reviewed. Patients with any other history of steroid therapy and intraocular surgery except cataract surgery were excluded. Baseline IOP was defi ned as the pre-injection mean IOP for two consecutive visits before the first injection and the final IOP was defi ned as the mean IOP for two consecutive visits measured at first month after the last injection. Signifi cant IOP elevation was defi ned as IOP elevation higher than 5 mmHg or final IOP higher than 21 mmHg provided that it is higher than baseline IOP.

Results: Hundred eighty three eyes (143 with AMD and 40 with diabetic macular oedema) from 160 patients were included in this study. IOP elevation after intravitreal anti-VEGF therapy was statistically signifi cant (P=0,0001 paired samples t-test). Sixteen eyes (8.7%) had IOP elevations greater than 5 mmHg, Ten (5.4%) had final IOPs higher than 21 mmHg. After the exclusion of patients with primary open angle glaucoma (PAOG) and pseudoexfoliation syndrome (PXS), two of 132 eyes in the ranibizumab group and two of 22 eyes in the bevacizumab group had final IOP values higher than 21 mmHg. The differences were statistically signifi cant (p=0.040, Pearson chi-square test).

Conclusion: IOP rise is more signifi cant in patients who received bevacizumab compared to ranibizumab. Hence ranibizumab injection might be recommended as a first choice especially in patients with POAG. Keywords : Vascular endothelial growth factor, ranibizumab, bevacizumab, intraocular pressure